{"symbol":"REGN","fiscalQuarter":"Q1-2019","reportDate":"2019-05-07","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2019","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS \u2014 Stock Down 6.34%","keyNumbers":[{"metric":"EPS","actual":"$4.45","expected":"N/A","surprise":"-23.47%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged the challenges faced in the quarter.","They emphasized ongoing investments in R&D despite the EPS miss."],"summary":"Management expressed concerns about current market conditions impacting earnings. They remain committed to long-term growth through research and development."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"The earnings report indicates that Regeneron Pharmaceuticals faced challenges this quarter, resulting in a significant EPS miss. The stock reacted negatively, dropping 6.34%. Investors are likely concerned about the company's ability to meet future earnings expectations without updated guidance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2019 earnings: EPS missed expectations. Stock down 6.34%. Full breakdown."}}